- Investing Ideas
- /
- Global Biotech Breakthroughs
Global Biotech Breakthroughs
Results
77
77 companies
Travere Therapeutics
Market Cap: US$1.5b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$17.94
7D
-13.7%
1Y
157.0%
Alnylam Pharmaceuticals
Market Cap: US$33.1b
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
ALNY
US$266.83
7D
-0.9%
1Y
76.9%
Ascelia Pharma
Market Cap: SEK 268.1m
A biotech company, focuses on orphan oncology treatments in Sweden.
ACE
SEK 2.67
7D
-7.3%
1Y
-70.0%
Elicera Therapeutics
Market Cap: SEK 103.5m
A clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden.
ELIC
SEK 2.95
7D
31.1%
1Y
126.1%
RemeGen
Market Cap: HK$21.5b
A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
9995
HK$26.50
7D
19.1%
1Y
-9.6%
Devyser Diagnostics
Market Cap: SEK 1.6b
Develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia.
DVYSR
SEK 96.00
7D
-9.9%
1Y
-7.7%
Akeso
Market Cap: HK$77.1b
A biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs.
9926
HK$85.90
7D
21.1%
1Y
88.4%
BioArctic
Market Cap: SEK 15.8b
Develops biological drugs for patients with disorders of the central nervous system in Sweden.
BIOA B
SEK 175.50
7D
-3.6%
1Y
-16.6%
Innate Pharma
Market Cap: €155.1m
A biotechnology company, develops immunotherapies for cancer patients in France and internationally.
IPH
€1.82
7D
-3.0%
1Y
-19.6%
Blueprint Medicines
Market Cap: US$5.5b
A precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
BPMC
US$90.01
7D
-0.8%
1Y
-2.4%
Legend Biotech
Market Cap: US$5.8b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$33.24
7D
-4.1%
1Y
-41.0%
Suzhou Zelgen BiopharmaceuticalsLtd
Market Cap: CN¥28.9b
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
688266
CN¥109.00
7D
13.2%
1Y
112.1%
Silence Therapeutics
Market Cap: US$114.3m
A biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
SLN
US$2.89
7D
-13.0%
1Y
-86.4%
RenovoRx
Market Cap: US$34.1m
A clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.00
7D
-2.0%
1Y
-20.6%
Madrigal Pharmaceuticals
Market Cap: US$7.2b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$334.60
7D
0.2%
1Y
36.4%
Abeona Therapeutics
Market Cap: US$216.0m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$4.68
7D
-6.2%
1Y
-41.9%
Vanda Pharmaceuticals
Market Cap: US$262.4m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.51
7D
-5.5%
1Y
-10.7%
Tenaya Therapeutics
Market Cap: US$88.4m
A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
TNYA
US$0.57
7D
-11.8%
1Y
-88.2%
Capricor Therapeutics
Market Cap: US$432.8m
A clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs.
CAPR
US$9.74
7D
-26.1%
1Y
43.2%
Aldeyra Therapeutics
Market Cap: US$326.9m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$5.33
7D
-15.5%
1Y
28.3%
OS Therapies
Market Cap: US$28.2m
A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
OSTX
US$1.51
7D
-7.4%
1Y
n/a
Soleno Therapeutics
Market Cap: US$3.1b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$73.67
7D
50.4%
1Y
76.4%
SpringWorks Therapeutics
Market Cap: US$3.1b
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.
SWTX
US$46.52
7D
0.09%
1Y
0.6%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$70.2b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally.
6990
HK$309.00
7D
7.3%
1Y
107.1%
CollPlant Biotechnologies
Market Cap: US$29.4m
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
CLGN
US$2.58
7D
-4.7%
1Y
-52.8%
Kiniksa Pharmaceuticals International
Market Cap: US$1.6b
A biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.
KNSA
US$21.85
7D
-4.0%
1Y
19.8%
aTyr Pharma
Market Cap: US$255.9m
A biotherapeutics company, engages in the discovery and development of medicines based on novel functions of tRNA synthetases in the United States.
ATYR
US$2.96
7D
-8.6%
1Y
60.0%
Precigen
Market Cap: US$422.0m
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$1.48
7D
-8.1%
1Y
5.7%
Arcutis Biotherapeutics
Market Cap: US$1.8b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$16.60
7D
0.8%
1Y
72.4%
Solasia Pharma K.K
Market Cap: JP¥7.2b
Engages in the development and marketing of oncology drugs in Japan and other Asian countries.
4597
JP¥33.00
7D
-8.3%
1Y
17.9%
Aelis Farma
Market Cap: €16.5m
A clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders.
AELIS
€1.20
7D
-1.6%
1Y
-90.8%
XOMA Royalty
Market Cap: US$231.2m
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
XOMA
US$19.78
7D
-6.4%
1Y
-23.4%
Invivyd
Market Cap: US$64.8m
A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
IVVD
US$0.58
7D
-5.9%
1Y
-85.3%
Shanghai Rightongene Biotechnology
Market Cap: CN¥1.2b
Shanghai Rightongene Biotechnology Co., Ltd.
688217
CN¥21.99
7D
2.2%
1Y
-19.6%
ABL Bio
Market Cap: ₩1.7t
A biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.
A298380
₩34,600.00
7D
2.4%
1Y
43.6%
SenzaGen
Market Cap: SEK 144.6m
Provides non-animal tests for assessing a substance’s allergenicity.
SENZA
SEK 4.84
7D
-4.2%
1Y
-20.7%